Nixon, an Intuitive veteran, said Capstan is focused primarily on mitral and tricuspid treatment, where it sees “significant ...

U.S. approval of an expanded indication for transcatheter aortic valve replacement in patients without symptoms is among the ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edwards Lifesciences outlines 2025 growth strategy, emphasizing innovations in TAVR and TMTT therapies, with a projected ...

Stock analysts at William Blair boosted their Q4 2025 earnings per share estimates for Edwards Lifesciences in a research ...

HighTower Advisors LLC cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 0.8% in the 3rd ...

In a report released yesterday, Richard Newitter from Truist Financial maintained a Hold rating on Edwards Lifesciences (EW – Research Report), ...

The global Structural Heart Devices market is expected to grow to USD 25.69 Billion by 2029, up from USD 16.31 Billion in ...

In a landmark decision (UPC_CFI_15/2023) delivered on November 15, 2024, the Unified Patent Court's Local Division in Munich (UPC, LDM) ruled in ...

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

Edwards Lifesciences Corporation ... full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and ...